Outcome
Type |
Measure |
Description |
Time frame |
Safety issue |
Primary |
Change from baseline intraocular pressure at month 1 follow up |
The intraocular pressure will be assessed by Goldmann Applanation Tonometry at baselines and month 1 follow up |
Baselines and month 1 follow up |
|
Primary |
Change from baseline intraocular pressure at month 3 follow up |
The intraocular pressure will be assessed by Goldmann Applanation Tonometry at baselines and month 3 follow up |
Baselines and month 3 follow up |
|
Primary |
Change from baseline intraocular pressure at month 6 follow up |
The intraocular pressure will be assessed by Goldmann Applanation Tonometry at baselines and month 6 follow up |
Baselines and month 6 follow up |
|
Primary |
Change from baseline intraocular pressure at month 12 follow up |
The intraocular pressure will be assessed by Goldmann Applanation Tonometry at baselines and month 12 follow up |
Baselines and month 12 follow up |
|
Secondary |
The complete success rate at month 3 follow up |
The complete success rate will be defined as intraocular pressure less than 18 mmHg with a 20 percent reduction without anti-glaucoma medication at month 3 follow up. |
Month 3 follow up |
|
Secondary |
The complete success rate at month 1 follow up |
The complete success rate will be defined as intraocular pressure less than 18 mmHg with a 20 percent reduction without anti-glaucoma medication at month 1 follow up. |
Month 1 follow up |
|
Secondary |
The complete success rate at month 6 follow up |
The complete success rate will be defined as intraocular pressure less than 18 mmHg with a 20 percent reduction without anti-glaucoma medication at month 6 follow up. |
Month 6 follow up |
|
Secondary |
The complete success rate at month 12 follow up |
The complete success rate will be defined as intraocular pressure less than 18 mmHg with a 20 percent reduction without anti-glaucoma medication at month 12 follow up. |
Month 12 follow up |
|
Secondary |
The qualified success rate at month 3 follow up |
The qualified success rate will be defined as intraocular pressure less than 18 mmHg with a 20 percent reduction with anti-glaucoma medication at month 3 followup. |
Month 3 follow up |
|
Secondary |
The qualified success rate at month 6 follow up |
The qualified success rate will be defined as intraocular pressure less than 18 mmHg with a 20 percent reduction with anti-glaucoma medication at month 6 followup. |
Month 6 follow up |
|
Secondary |
The qualified success rate at the month 12 follow up |
The qualified success rate will be defined as intraocular pressure less than 18 mmHg with a 20 percent reduction with anti-glaucoma medication at month 12 followup. |
Month 12 follow up |
|
Secondary |
The qualified success rate at the month 1 follow up |
The qualified success rate will be defined as intraocular pressure less than 18 mmHg with a 20 percent reduction with anti-glaucoma medication at month 1 followup. |
Month 1 follow up |
|
Secondary |
Change from baseline the number of glaucoma medications at month 1 follow up |
The number of glaucoma medications will be assessed at baseline and month 1 follow up. |
Baseline and month 1 follow up |
|
Secondary |
Change from baseline the number of glaucoma medications at month 3 follow up |
The number of glaucoma medications will be assessed at baseline and month 3 follow up. |
Baseline and month 3 follow up |
|
Secondary |
Change from baseline the number of glaucoma medications at month 6 follow up |
The number of glaucoma medications will be assessed at baseline and month 6 follow up. |
Baseline and month 6 follow up |
|
Secondary |
Change from baseline the number of glaucoma medications at month 12 follow up |
The number of glaucoma medications will be assessed at baseline and month 12 follow up. |
Baseline and month 12 follow up |
|
Secondary |
Change from baseline the best-corrected visual acuity at month 6 follow up |
The best-corrected visual acuity will be assessed using the Snellen chart at baseline and month 6 follow up. |
Baseline and month 6 follow up |
|
Secondary |
Change from baseline the best-corrected visual acuity at month 12 follow up |
The best-corrected visual acuity will be assessed using the Snellen chart at baseline and month 12 follow up. |
Baseline and month 12 follow up |
|
Secondary |
Complications at month 1 follow up |
The complications of surgery will be assessed at month 1 follow up. |
Month 1 follow up |
|
Secondary |
Complications at month 3 follow up |
The complications of surgery will be assessed at month 3 follow up. |
Month 3 follow up |
|
Secondary |
Complications at month 6 follow up |
The complications of surgery will be assessed at month 6 follow up. |
Month 6 follow up |
|
Secondary |
Complications at month 12 follow up |
The complications of surgery will be assessed at month 12 follow up. |
Month 12 follow up |
|
Secondary |
Need to postoperative needling and laser goniopuncture at month 1 follow up |
Need to postoperative needling and laser goniopuncture at month 1 follow up |
Month 1 follow up |
|
Secondary |
Need to postoperative needling and laser goniopuncture at month 3 follow up |
Need to postoperative needling and laser goniopuncture at month 3 follow up |
Month 3 follow up |
|
Secondary |
Need to postoperative needling and laser goniopuncture at month 6 follow up |
Need to postoperative needling and laser goniopuncture at month 6 follow up |
Month 6 follow up |
|
Secondary |
Need to postoperative needling and laser goniopuncture at month 12 follow up |
Need to postoperative needling and laser goniopuncture at month 12 follow up |
Month 12 follow up |
|